19 / 19
Volume 6, Issue 8(Suppl)
J Gastrointest Dig Syst 2016
ISSN:2161-069X JGDS, an open access journal
Page 74
Digestive Diseases 2016
December 08-09, 2016
conferenceseries
.com
Digestive Diseases
December 08-09, 2016 Dubai, UAE
International Conference on
J Gastrointest Dig Syst 2016, 6:8(Suppl)
http://dx.doi.org/10.4172/2161-069X.C1.047Prevalence of steatosis and advanced liver fibrosis in infected patients with HIV Bukavu Provincial
Hospital: Preliminary study
Patrick de Jésus Ngoma
1, 2
, Rinelle Etinkun
1
, Ghislain Maheshe
1
, Aimé Murhula
1
, Lupande David
1, 2
, Yannick Samafundu
2
, Hassan Mwana-Yile
2
, Antoine
Tshimpi
2
, Charles Mbendi
2
, René Fiasse
3
and
Jeff Kabinda
1
1
Provincial General Hospital in Bukavu Reference - Catholic University of Bukavu, Congo
2
University of Kinshasa, Congo
3
Cliniques Universitaires Saint-Luc, Belgium
Introduction:
Today, there is an increase in the prevalence of fatty liver including in people infected with HIV (PHIV) worldwide.
Objectives:
To assess the prevalence and risk factors associated with fatty liver in PHIV tracked Bukavu general reference to provincial
hospital (HPGRB) and to determine the prevalence of advanced liver fibrosis in these patients.
Method:
It is a cross-sectional study conducted from March 5 till November 20, 2015 which included 70 patients infected with
HIV as they presented themselves to the HPGRB during the study period. All realized abdominal ultrasound with CHISON i3 or
SONOSCAPE S11 device with a convex probe of 3.5 MHz in addition to laboratory tests to calculate the NAFLD fibrosis score online.
Results:
Majority of our study population was aged over 35 years (74.3%) with a predominance of males (58.6%). 10% were
overweight; 20% had a moderate alcohol consumption; 1.4% had diabetes; 38.5% were clinical stage 3 of the WHO and 8.7% in
stage 4. The median CD4 count was 124 (19-618) cells / microliter. 62.9% of patients were treated with AZT+3TC+NVP; 10% in
TNF+3TC+EFV; 7.1% for EFV+TNF+EMTRIC. The prevalence of hepatic steatosis was 59.2% and 14.2% of patients had advanced
liver fibrosis. Factors associated with steatosis were an albumin level of less than 3.5 g/ dL OR=10.8 (1.5 to 264.6) p=0.02; elevation of
alanine aminotransferase (ALT) OR=3.2 (1.1 to 9.8) p=0.02.
Conclusion:
Prevalence of hepatic steatosis in our study population was high (59.2%). Hypo albumin and ALT elevation are biological
factors associated with the presence of this steatosis (p=0.02).
kabindaalu@gmail.com